Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 2UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 8Head & Neck 4Thoracic 3Breast 3Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 485Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
lobaplatin × Breast × Clear all
NCT07093931 2025-07-30

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Shandong Cancer Hospital and Institute

Phase 4 Not yet recruiting
468 enrolled
Breast

Breast Neoplasms

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01483300 2012-01-24

Effectiveness and Toxicity of Gemcitabine/Lobaplatin Versus Gemcitabine/Cisplatin as Second-line Treatment in Metastatic Breast Cancer

Harbin Medical University

Phase 2 Unknown
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡